NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020David S. Ettinger, Douglas E. Wood, Charu Aggarwal et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 1k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung CancerAlexander Drilon, Vivek Subbiah, Lyudmila Bazhenova et al.|New England Journal of Medicine|2020Cited by 835
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018David S. Ettinger, Miranda Hughes, Dara L. Aisner et al.|Journal of the National Comprehensive Cancer Network|2018Cited by 471
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A. Yu, Pasi A. Jänne, Yasushi Goto et al.|Journal of Clinical Oncology|2023Cited by 224
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung CancerLeora Horn, Christine M. Lovly, Jennifer G. Whisenant et al.|Journal of Thoracic Oncology|2019Cited by 163